A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer

被引：0
|
作者：
Borges, Virginia F.
Chan, Arlene
Lin, Nancy U.
Tonda, Margaret Eleanor
Shilkrut, Mark
Alemany, Carlos A.
机构：
[1] Univ Colorado, Canc Ctr, Aurora, CO USA
[2] Breast Canc Res Ctr WA, Nedlands, Australia
[3] Curtin Univ, Nedlands, Australia
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Olema Oncol, San Francisco, CA USA
[6] AdventHlth Orlando, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1127
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
    Hamilton, Erika
    Pusztai, Lajos
    Soliman, Hatem H.
    Hurvitz, Sara
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    Marreddy, Priya
    Sahmoud, Tarek
    Ibrahim, Nuhad
    CANCER RESEARCH, 2023, 83 (05)
  • [22] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).
    Munster, Pamela N.
    Hamilton, Erika Paige
    Franklin, Catherine
    Bhansali, Suraj
    Wan, Kitty
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [25] Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)
    Majid, Oneeb
    Xiao, Jianjun Alan
    Sahmoud, Tarek
    Yasuda, Sanae
    Cantagallo, Lisa
    Hamilton, Erika P.
    Pluard, Timothy
    Juric, Dejan
    Gualberto, Antonio
    Husseiin, Ziad
    CANCER RESEARCH, 2021, 81 (04)
  • [26] A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
    Hamilton, Erika
    Alemany, Carlos
    Lin, Nancy U.
    Klein, Pamela M.
    Trinh Le
    Kushner, Peter J.
    Harmon, Cyrus
    Zujewski, Jo Anne
    Patel, Manish
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2-metastatic breast cancer.
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] The Evolving Use of SERDs in Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeselsohn, Rinath M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 428 - 431
  • [29] A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
    Ma, Cynthia
    Luo, Jingqin
    Moss, Jessica
    Kwa, Maryann
    Parajuli, Ritesh
    Khoury, Katia
    Douglas, Emily
    Frith, Ashley
    Rigden, Caron
    Ademuyiwa, Foluso
    Thomas, Shana
    Haas, Brittney
    Wulf, Gerburg
    Dees, Claire
    Said, Rabih
    CANCER RESEARCH, 2024, 84 (09)
  • [30] FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Gao, Jennifer J.
    Osgood, Christy L.
    Feng, Zhou
    Bloomquist, Erik W.
    Tang, Shenghui
    Chang, C. J. George
    Ricks, Tiffany K.
    Hou, Sherry C.
    Pierce, William F.
    Rivera, Donna R.
    Pazdur, Richard
    Kluetz, Paul G.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5008 - 5011
12345